Tobin Schilke, CFO at Revance Therapeutics, Inc. (RVNC), sold 6,402 shares at $31.70 ($203K) on 2023-05-01, disclosed to the SEC on 2023-05-02.
Scheduled sale ($203k) by CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.70 | 3,201 | $101K | 50.0% |
| 2 | $31.70 | 3,201 | $101K | 50.0% |
| Total | $31.70 avg | 6,402 | $203K | 100% |
| Filing → |
| RVNC | SELL | 2023-07-05 | $43K | — | Filing → |
| RVNC | SELL | 2023-06-05 | $181K | — | Filing → |
| RVNC | SELL | 2023-05-16 | $1.5M | — | Filing → |